Edwards Lifesciences had its Relative Strength (RS) Rating upgraded from 65 to 73 Monday — a welcome improvement, but still shy of the 80 or better score you look for.
IBD's unique RS Rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners often have an RS Rating of above 80 as they begin their biggest climbs. See if Edwards Lifesciences can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
Edwards Lifesciences is working on a flat base with a 96.12 entry. See if the stock can clear the breakout price in heavy trade.
While revenue growth fell last quarter from 14% to 9%, the bottom line grew 6%, up from 0% in the prior report.
The company holds the No. 16 rank among its peers in the Medical-Products industry group. LeMaitre Vascular, Globus Medical and Lantheus Holdings are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
